<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>806</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>12391202</PubmedId>
            <Abstract>In this study, we describe the synthesis of various lipopeptides based on the sequence of luteinizing hormone-releasing hormone (LHRH) and report on their abilities to induce Abs against this "self" hormone when inoculated into mice in the absence of additional adjuvant. The peptides consisted of a colinear CD4(+) T helper cell epitope from the L chain of influenza virus hemagglutinin and LHRH, which has B cell epitopes but no T cell epitopes present in its sequence. Lipids were attached either at the N terminus or between the T cell epitope and LHRH, in the approximate center of the peptide. The lipopeptide constructs displayed different solubilities and immunological properties that depended not only on the lipid content but also on the position of attachment of the lipids. Some of these constructs were highly immunogenic, inducing high titers of Ab, which were capable of efficiently sterilizing female mice when administered in saline by s.c. or intranasal routes. The most effective vaccines were highly soluble, contained the dipalmitoyl-S-glyceryl cysteine moiety, and had this lipid attached at the center of the molecule. The relative ability of the lipopeptides to induce an Ab response in the absence of external adjuvant was reflected by their ability to up-regulate the surface expression of MHC class II molecules on immature dendritic cells. These results demonstrate that the composition and position within peptide vaccines of self-adjuvanting lipid groups can influence the ability to induce the maturation of dendritic cells and, in turn, the magnitude of the resulting Ab response.</Abstract>
            <ArticleYear>2002</ArticleYear>
            <ArticlePages>4905-12</ArticlePages>
            <ArticleTitle>Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Zeng</LastName>
                    <ForeName>Weiguang</ForeName>
                </Author>
                <Author>
                    <LastName>Ghosh</LastName>
                    <ForeName>Souravi</ForeName>
                </Author>
                <Author>
                    <LastName>Lau</LastName>
                    <ForeName>Yuk Fai</ForeName>
                </Author>
                <Author>
                    <LastName>Brown</LastName>
                    <ForeName>Lorena E</ForeName>
                </Author>
                <Author>
                    <LastName>Jackson</LastName>
                    <ForeName>David C</ForeName>
                </Author>
            </Authors>
            <Affiliations>Cooperative Research Center for Vaccine Technology, Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia.</Affiliations>
            <ArticleChemicalList>Adjuvants, Immunologic;Histocompatibility Antigens Class II;Immunoglobulin G;Immunoglobulin M;Lipoproteins;Vaccines, Contraceptive;Gonadotropin-Releasing Hormone;tripalmitoyl cysteine;Cysteine</ArticleChemicalList>
            <ArticleMeshHeadingsList>Adjuvants, Immunologic(administration &amp; dosage; chemical synthesis); Administration, Intranasal; Amino Acid Sequence; Animals; Cells, Cultured; Cysteine(administration &amp; dosage; analogs &amp; derivatives; immunology); Dendritic Cells(immunology; metabolism); Female; Gonadotropin-Releasing Hormone(immunology); Histocompatibility Antigens Class II(biosynthesis); Immunoglobulin G(biosynthesis); Immunoglobulin M(biosynthesis); Injections, Subcutaneous; Lipoproteins(administration &amp; dosage; chemical synthesis; immunology); Male; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Solubility; Vaccines, Contraceptive(administration &amp; dosage; chemical synthesis; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>169</Volume>
                <Issue>9</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>LHRH</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>EHWSYGLRPG</LinearSequence>
                        <StartingPosition>1</StartingPosition>
                        <EndingPosition>10</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>1714374A</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10090</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 4905</LocationOfData>
                <EpitopeId>12375</EpitopeId>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>This peptidic hormone is said to harbor at least one B cell epitope. Sequence is QHWSYGLRPG in Swiss-Prot entry. Swiss-Prot entry is also named Progonadoliberin I precursor, containing LHRH.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>9149</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-8 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>EHWSYGLRPG</LinearSequence>
                                            <StartingPosition>1</StartingPosition>
                                            <EndingPosition>10</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>1714374A</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10090</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>T-Lys-(Ser-Ser)-B</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Fatty acid conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Other</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>2 doses, 28 days apart, of 20, 10 or 1 nmol.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Results are similar with different doses and with intranasal administration. CD4 T cell epitope GALNNRFQIKGVELKS included to enhance immunogenicity. The carrier was composed of Palmitic Acid.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>0</NumberOfSubjectsResponded>
                            <AssayComments>Administration of the epitope with lipidic molecules not covalently bound as carriers did not induce an anti-self hormone response, while the same molecule covalently attached as a carrier had strong adjuvant properties.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>LHRH</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EHWSYGLRPG</LinearSequence>
                                        <StartingPosition>1</StartingPosition>
                                        <EndingPosition>10</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>1714374A</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2 and table 3</LocationOfData>
                        <BCellId>9147</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-8 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>EHWSYGLRPG</LinearSequence>
                                            <StartingPosition>1</StartingPosition>
                                            <EndingPosition>10</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>1714374A</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10090</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>T-Lys-(Ser-Ser)-B</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Fatty acid conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Other</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>2 doses, 28 days apart, of 20, 10 or 1 nmol.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Results are similar with different doses and with intranasal administration. CD4 T cell epitope GALNNRFQIKGVELKS included to enhance immunogenicity. The carrier was composed of Palmitic Acid.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Administration of the epitope in conjunction with different lipidic carriers having adjuvant properties was performed. The carriers were found to be most effective when located in a branched construct, in the middle of the self epitope and with a T cell epitope. The results of Ab titers correlate strongly with the fertility status of the animals.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>LHRH</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EHWSYGLRPG</LinearSequence>
                                        <StartingPosition>1</StartingPosition>
                                        <EndingPosition>10</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>1714374A</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

